A peer-level look at how dermatologists are responding to DTC skincare and teledermatology, from asynchronous photo assessment and compounded topical regimens to adverse effects, practice impact, and regulation.
Audience: Dermatologists
Countries: 4
Completion Rate: 64.3%
SGID:8946728
-Hero findings
– Quick Read — Key Findings
For acne, skincare, hair concerns, and other visible conditions, patients can increasingly start with a digital intake, photographs, asynchronous messaging, and treatment shipped directly to the home.
That convenience changes where dermatologists enter the journey: some patients arrive only after an online regimen has failed, irritation has developed, the diagnosis is uncertain, or the history is incomplete. The American Academy of Dermatology’s teledermatology standards emphasize board-certified, dermatologist-directed care, adequate history and examination before prescribing, record access, and an in-person option when needed. The MDForLives survey examines how dermatologists experience that shift, how much DTC use they see, what they consider risky, where they trust asynchronous assessment, how they view compounded topicals, and which safeguards should define a more accountable model.
50.0% report no noticeable effect on patient volume or revenue, while 40.0% describe a moderate negative effect from reduced straightforward aesthetic or acne consultations.
Half call the impact neutral, but 40.0% report a moderate negative effect and 6.7% a severe one tied to fragmented continuity and loyalty, while only 3.3% see a positive filtering effect. The upstream signal matters more than the volume: 32.3% say fewer than 10% of patients have used an online service before the visit and 29.0% put it at 10% to 25%, so DTC is already changing case mix and what unresolved risk follows the patient back into clinic before it changes total volume.
40.0% are moderately confident in asynchronous photo-based assessment only when it is conducted by a board-certified dermatologist, while 30.0% are not confident at all without palpation, dermoscopy, and full examination.
Only 6.7% are highly confident even for low-complexity conditions, 20.0% say photos are often insufficient for grading or differential diagnosis, and 3.3% depend on AI support. The risk question sharpens it: misdiagnosis or delayed diagnosis of serious conditions is the single greatest clinical risk for 33.3%, ahead of stewardship, monitoring gaps, skin damage, and fragmented history, so asynchronous care is judged less by the channel than by who decides and what an image cannot show.
40.0% take a neutral view and consider these regimens comparable to standard standalone FDA-approved topicals, while 23.3% are unfavorable because of concerns about stability and potency testing.
The spread shows why this is not binary: 13.3% see value in customization and adherence, 16.7% consider the combinations unnecessary and potentially more irritating, and 6.7% accept them only from a licensed compounding pharmacy with clear labeling. Because the FDA notes compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality, provenance, labeling, formulation quality, and counseling become clinically relevant whenever a compounded regimen enters care.
60.0% say they see adverse effects, treatment failures, or skin barrier damage from DTC online dermatology regimens a few times per month.
Another 10.0% see these problems daily or weekly, 23.3% a few times a year, 3.3% never, and 3.3% are unsure because patients do not always disclose prior DTC use. It matters because the dermatologist is often treating more than the visible reaction, needing to reconstruct what was prescribed, how products were layered, whether monitoring occurred, and whether the original diagnosis was correct.
50.0% say they have no plans to adopt digital or subscription-based models, while 23.3% plan to implement teledermatology or digital services within the next 12 months.
A smaller group already competes digitally: 10.0% offer teledermatology and 13.3% offer subscriptions or retail dispensaries, while 3.3% deliberately differentiate through procedural, surgical, or complex medical dermatology. There is no single strategic response, some add convenience, some hold the traditional model, and some lean into services that are hard to commoditize online.
51.7% identify greater convenience as DTC dermatology’s biggest advantage, while 58.6% say the most urgent reform is a strict requirement for consultations to be conducted by board-certified dermatologists.
Instant access and the end of multi-week waits attract 24.1%, and transparent pricing another 24.1%. On policy, 17.2% want mandatory real-time video before prescribing, 10.3% want DTC records in central EHRs, and 6.9% each want stronger compounding oversight or standardized monitoring for oral medicines, echoing the AAD standards on dermatologist-directed care, adequate history and examination, record access, and an in-person option.
The survey gives convenience its due: more than half call it the strongest advantage of DTC platforms, and faster access, home delivery, and transparent pricing solve real frictions in the patient journey.
But the same data shows where the model becomes clinically fragile. Diagnostic confidence depends heavily on clinician expertise and the ability to escalate beyond photographs, compounded regimens raise questions about formulation quality, labeling, and follow-up, and adverse effects and treatment failures are already returning to practices, sometimes with incomplete histories.
The unresolved question is not whether digital dermatology belongs in care, but whether convenience can be built around the same clinical fundamentals patients expect in person: accountable expertise, sufficient examination, transparent prescribing, reliable records, monitoring, and an accessible route back to in-person dermatology when the case no longer fits the screen.
You have read the summary
Common questions about asynchronous skin assessment, teledermatology, compounded treatments, and when digital care should escalate to an in-person dermatologist.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
